Eomesodermin is an essential early gene in Xenopus mesoderm formation and shows a morphogen-like response to activin. Here we de®ne the regions of the Eomesodermin promoter required for mesodermal expression and for concentration-dependent response to activin. We ®nd an activin response element (ARE) located between 25.6 and 25.0 kb which contains two critical FAST2 binding sites. The ARE alone is necessary and suf®cient for concentration-dependent response to activin. A 5.6 kb promoter recapitulates Eomes expression in normal mesoderm cells. A repressor element extinguishes Eomes expression in the endoderm. We relate our results to mesoderm patterning in early Xenopus development and to a mechanism of morphogen gradient response. q
Introduction
One mechanism by which tissue-speci®c differentiation is achieved in metazoans is through regional activation of gene transcriptions in early embryos. Owing to its rapid rate of development, easy accessibility and experimental manipulability, Xenopus is a useful organism in which to study how germ layer-speci®c gene expression occurs. As mesoderm is the earliest induced embryonic tissue in Xenopus, for which there is also an abundance of early gene markers (Stennard et al., 1997) , it is a natural choice for further study of mechanisms of developmental gene regulation.
Recent progress has been made in identifying some of the molecular components of early signalling pathways important in germ layer speci®cation. Formation of the full range of early mesodermal cell types requires several maternally encoded, vegetally localized signalling pathways. This includes the early-acting dorsalization pathway (for a review see Moon and Kimelman, 1998) , and a second, mesoderm inducing pathway, which appears to act slightly later and entails cell±cell communication. This inducing pathway in Xenopus is thought to work through secreted factor members of both the FGF family (Slack et al., 1989; Smith et al., 1989; Amaya et al., 1991) and the TGF-b superfamily (Smith et al., 1988; Thomsen et al., 1990; Hemmati-Brivanlou and Melton, 1992; Dyson and Gurdon, 1997) . Both of these gene families are also important in endoderm differentiation (Cornell et al., 1995; Henry et al., 1996; Zorn et al., 1999) .
As the TGF-b factor activin is capable of inducing a full range of early mesodermal genes and cell types, it has frequently been used in studying gene promoter activation. Activin and other TGF-b factors signal by direct phosphorylation of Smad proteins (Derynck et al., 1996; Graff et al., 1996) and association with cellular transcription factors (Wotton et al., 1999 ; for a review see Zhang and Derynck, 1999) . The receptor-activated Smads (Smads 2 and 3) are phosphorylated by activated activin and TGF-b receptor type I kinases, respectively, enabling them to form heterooligomers with the DNA binding`common' Smad (Smad 4; Lagna et al., 1996; Wu et al., 1997) . These Smad complexes then travel to the nucleus, form protein-DNA complexes with other transcription factors like FAST proteins (in the case of activin and TGF-bs; Chen et al., 1996 Chen et al., , 1997 Labbe Â 
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A number of early Xenopus gene promoters have been analyzed to date, among which the ones most relevant to this study are those expressed in the mesoderm and endoderm (see below). The activin response gene Mix.2 is expressed throughout the endoderm and mesoderm (Huang et al., 1995; Vize, 1996) . Its promoter contains an activin responsive element (ARE; Chen et al., 1996) that mediates signalling through the Smad/FAST pathway (Chen et al., 1997) . Another mesendodermal gene, Bix.1, appears to be regulated by Xbra and VegT/Apod (Tada et al., 1998) . Xbra is pan-mesodermal, and its promoter, like the endogenous gene, responds to FGF and to low doses of activin, but is inhibited by high activin concentrations (Latinkic et al., 1997) or by gsc (Artinger et al., 1997) . Consistent with this modulated Xbra response, there appear to be at least several co-operative cis-acting regulatory regions within the Xbra promoter (Latinkic et al., 1997) . A general theme in Xenopus promoter analysis to date is a lack of extensive sequence similarity among the various AREs (and activin responsive regions) that have been identi®ed.
Eomes is a crucial early gene in Xenopus mesoderm differentiation (Ryan et al., 1996) , and its recently cloned mouse homologue (Wattler et al., 1998) is required for the epithelial-mesenchymal transition which characterizes primitive streak and node formation (Russ et al., 2000) . Eomes is also expressed later in development in the forebrain (Ryan et al., 1998; Ciruna and Rossant, 1999; Hancock et al., 1999; Kimura et al., 1999) , where it is important in neuronal differentiation (Ryan and Gurdon, in preparation) . Eomes encodes a transcription factor of the T-box family, of which brachyury (Smith et al., 1991) is the founding member. It is among the few earliest mesoderm-speci®c genes, and can ectopically activate most early mesodermal genes, suggesting a role at the head of a mesoderm gene cascade. Its requirement for mesoderm development is indicated by the effect of a dominant negative Eomes-engrailed fusion construct (Ryan et al., 1996) .
A particularly interesting feature of early Eomes induction is its concentration-dependent responsiveness to activin. The early expression of Eomes is in a dorsal to ventral gradient across the future mesoderm. Animal cap cells show the same graded response when treated with increasing concentrations of activin, but this gene does not respond to eFGF or early Wnt signalling (Ryan et al., 1996) . This situation is an exceptionally simple system in which to analyze the mechanism by which cells make a concentration-related response to a known signalling molecule or morphogen. Previous work from this laboratory has shown that cells respond to three-fold increases in activin concentration by only a three-fold difference in receptor occupancy (Dyson and Gurdon, 1998) and by a three-fold difference in nuclear Smad concentration (Shimizu and Gurdon, 1999) . The desirable next step in this analysis is to identify the region of an early mesoderm gene promoter that shows a concentration-related response to activin.
In order to achieve this, we have made a detailed investigation of the promoter of Xenopus Eomesodermin. We have de®ned a particular region of its promoter that gives correct developmental expression and that also shows a normal pattern of response to activin concentration.
Results

A genomic clone represents an expressed Eomes gene
We used a probe generated from the ®rst 200 bp of the Eomes cDNA (Ryan et al., 1996) within the 5 H untranslated region (UTR) to screen a Xenopus muscle genomic library cloned in Lambda FIX w II (Stratagene). Screening 2 million clones from this library yielded four positive clones (numbered 1, 3, 5 and 8). Sequencing of clones 3 and 5 upstream of the Eomes 5 H UTR revealed a nearby TATA box (Fig. 1A, underlined) . We therefore used PCR to generate RNase protection clones spanning the region of the putative start site. Using these probes in an RNase protection assay, we ®nd that each of the four genomic clones (1, 3, 5 and 8) represents a gene that is expressed in Xenopus development (Fig. 1B, stage 11) , and that the protected fragment lengths were as expected. Furthermore, these expressions display the same temporal kinetics of accumulation as the original Eomes mRNA (Ryan et al., 1996 (Ryan et al., , 1998 (Fig. 1B) . Further sequencing data revealed a 99% identity within the coding region near the transcription start site of clone 3 compared to the original Eomes cDNA, which we therefore chose for further analysis.
To more precisely de®ne the start site of Eomes transcription, we used primer extension analysis (Fig. 1C , lane PE) employing three antisense primers (EP59, 60, 61) each 10 nucleotides apart within the Eomes 5 H UTR. In agreement with the RNase protection assay results, each primer gave the expected length extension product, locating the start of transcription to an adenosine residue (Fig. 1A, 11 under thick arrow). Depending on the primer used, a major stop was alternately found at T (Fig. 1A , thick arrow alone). These data indicate that the TATA box is located at 234. In conclusion, Eomes genomic clone 3 is expressed with the same kinetics as the original Eomes mRNA, and therefore represents a good candidate for an Eomes gene.
Structure of an Eomes genomic clone
We sequenced nearly the entire 14 kb Eomes genomic clone 3, including 8.5 kb of promoter (GenBank accession number AF179418), revealing a typical RNA polymerase II (pol II) promoter structure near the start site of transcription; the Eomes gene contains, in addition to the TATA box, two CCAAT boxes at 2178 and 2213 (Fig. 1A, underlined) . Mapping studies (data not shown) revealed a number of restriction enzyme sites present within the 8.5 kb promoter region. The 5.0 kb of Eomes coding region present within clone 3 contains a 222 bp 5 H UTR and the ®rst six exons of the Eomes gene encoding the N-terminal two-thirds of the Eomes protein (Fig. 1D) . The Eomes intron/exon structure was deduced by comparing its sequence to that of the Eomes cDNA. In each case canonical GT/AG splice donor/acceptor sites were found¯anking each intron. We found that exons I through VI (spanning 1537 bp) were 99% identical overall to the original Eomes cDNA. Based on temporal expression kinetics (discussed above; Fig. 1B ) and coding sequence, we conclude that genomic clone 3 represents an expressed Xenopus Eomes gene.
The Eomes promoter can be used to drive a heterologous globin reporter gene
To test whether the Eomes 5
H¯a nking genomic sequence could be used to drive the expression of a heterologous reporter gene, we fused the 8.5 kb Eomes promoter 5
H to the coding region of the human b-globin gene, which starts at the globin initiator methionine and includes all three bglobin exons ( Fig. 2A , top diagram) (Mohun et al., 1989; Howell and Hill, 1997) . We injected Eomes-globin plasmids into the animal pole of Xenopus embryos at the one-to twocell stage and allowed these embryos to develop until a midblastula stage (Fig. 2B) . Animal pole cells (animal caps) were dissected, and either treated with activin protein or left untreated until a mid-gastrula stage, when they were assayed for gene transcripts. As a control for levels of injected plasmid gene expression, we used the constitutively active EF1-a promoter fused to human globin from which the last 50 bp of b-globin exon II have been removed (Mohun et al., 1989) (Fig. 2A, bottom diagram) . These injected plasmids drive expression of human globin RNA in activin-treated animal caps, yielding ®ve different globin RNA fragments in an RNase protection assay (Fig. 2C ). For plasmid DNA and unspliced RNA, Eomes-globin yields a 434 nucleotide (nt) protected fragment ( Fig. 2A , see numbered segments above and below globin), while Refglobin fragments are 50 bp smaller at 384 nt. For correctly spliced RNA, the missing introns are degraded in the probe. This leaves two protected fragments per reporter, one corresponding to each exon. Globin exon I is common to both constructs, and yields a 94 nt protected probe fragment. Eomes-globin exon II produces a 208 nt fragment, and Ref-globin 158 nt. For simplicity we henceforth show only the 208 and 158 nt fragments.
The Eomes promoter contains an activin response element
In order to locate any element(s) acting in cis in the Eomes response to activin, we generated an initial 5 H deletion series in Eomes-globin by digestion with appropriate restriction enzymes, yielding 6.5, 4.0, 1.8 kb and 253 bp promoter constructs. We tested these constructs in animal caps that were either treated with 32 U/ml (Green et al., Fig. 1 . Several Eomes genomic clones represent genes expressed in Xenopus development. (A) Eomes genomic sequence (sense strand)¯anking the transcription start site reveals a TATA box (234) and two CCAAT boxes (2178, 2213) . The transcription start site is marked by 11 and thick arrows; thin arrows mark weak reverse transcriptase stops. (Note that the sequence data shown on the gel in (C) is antisense, while that shown in (A) is sense strand.) (B) RNase protection analysis of several independent Eomes genomic clone isolates using probes spanning the transcription start site. Clones are numbered 1, 3, 5 and 8 (above lanes). Control probes 5 H U (Eomes 5 H UTR), and PC (Eomes 3 H UTR) are indicated above lanes. RNA was isolated from eggs (E), mid-gastrula (11) or tailbud (28) 1992; Howell and Hill, 1997) activin protein or left untreated. To do this, we injected as DNA a mixture of the 8.5 kb (or each deleted) Eomes-globin construct plus Ref-globin as described above. RNA was prepared as previously described and used in an RNase protection assay (Ryan et al., 1996) for either human globin or Eomes, Xbra and FGF-receptor (FGF-R) transcripts. The results indicate that sequences between 26.5 and 24.0 kb fully confer activin responsiveness to the Eomes promoter; the 6.5 and 8.5 kb promoters are equivalently active within error, while the 4.0 kb promoter is unresponsive to activin ( Fig. 3A ; quantitation and diagram of deletions shown in Our sequence data revealed three FAST2 binding sites (Labbe Â et al., 1998) within the Eomes promoter, at 25.2, 25.1 and 23.4 kb, respectively (Fig. 3C, arrowheads) . Two of these sites are removed by deletion to 24.0 kb, which as mentioned above also abolishes responsiveness to activin, implicating these sites in Eomes activation. We therefore made two further 5 H end deletions, at XbaI (25.6 kb) and NcoI (25.0 kb), closely bracketing the two FAST2 sites. On testing these two constructs in animal caps we found that sequences between 25.6 and 25.0 kb within the Eomes promoter confer full activin responsiveness to the Eomes promoter ( Fig. 3B ; compare lanes 5.6 with 5.0). As a measure of reproducibility, all promoter constructs (except 253 bp) were assayed at least in triplicate, which is shown for comparison for the 5.6 and 5.0 kb Eomes promoters in Fig. 3B . To reduce batch variability we ®nd it necessary to directly compare test and control constructs in eggs from the same female. Uninjected control Xenopus embryos contain no human b-globin transcripts, as expected (Fig. 3B , lane WE).
Quantitation of the results from several assays including the ones shown in Fig. 3A ,B revealed a ten-fold mean reduction in Eomes-globin response to activin on deletion of sequences between 25.6 and 25.0 kb within the Eomes promoter (Fig. 3C ). We found that the 8.5, 6.5 and 5.6 kb promoters were all activated by activin to a similar degree, and that 5 H end deletions to 5.0 kb and further were all equally inactive within error.
In conclusion, we ®nd that a 571 bp region within the distal Eomes promoter containing two FAST2 transcription factor binding sites is necessary for Eomes response to activin signalling, while a more proximal region containing a FAST2 site found at 23.4 kb has no effect on its own in this assay.
DNA elements important in Eomes activin responsiveness
To speci®cally assess the role of these distal FAST2 sites (at 25.1 and 25.2 kb, called F1 and F2, respectively) in mediating the transcriptional activation of the Eomes promoter in response to activin, we used PCR to generate a double point mutation in each FAST2 site individually (Fig. 4A ). This double point mutation has been shown by Labbe Â et al. (1998) to speci®cally prevent FAST2 binding to the mouse gsc promoter and block gsc activation in response to TGF-b. As shown in Fig. 4B , similarly mutating either FAST2 site individually (lanes F1m and F2m, plus FAST2) results in a promoter to which in vitro translated mouse FAST2 (or Xenopus FAST1; Bourillot and Gurdon, in preparation) protein still binds in an electrophoretic mobility shift assay, compared to the wild type sequence (lane WT, plus FAST2). In contrast to the singly mutated constructs, when both FAST2 sites are mutated, binding is completely abolished (Fig. 4B , lane F1F2m plus FAST2 versus lane Lysate con.). We note that while the WT probe yields two distinct, well-resolved complexes with FAST2 (arrowheads), the F1m and F2m probes each yield a single shift species, perhaps re¯ecting their only having one intact FAST2 site. Also, the F1m complex migrates more slowly, and the F2m complex slightly more quickly than the faster of the two WT complexes (see below), perhaps due to a slightly different protein-DNA conformation in each case. Taken together, these data con®rm that our mutations abolish the binding of FAST2 to either one or both FAST2 sites within the Eomes promoter.
On testing these mutated constructs in animal caps with or without activin, promoters containing individually mutated sites still respond to activin (Fig. 4C , lanes F1m and F2m,^activin [A] ), but at a reduced level (normalized to Ref-globin) compared to that seen for the wild type promoter (lane 5.6). On average, the F1m construct is less active in this assay than the F2m construct, which correlates with their respective binding properties mentioned above. However, we feel that the error in measuring Eomes-globin promoter activations in caps precludes a de®nitive correlation between transcriptional activity and binding for these two constructs (see below, Fig. 4D ).
In contrast with individual mutations, when both FAST2 sites are destroyed we obtain an activin non-responsive Eomes promoter indistinguishable from the control 5.0 kb construct missing these sites (Fig. 4C , compare lanes F1F2m to 5.0). Quantitation of the results shown in Fig. 4C con®rms these results (Fig. 4D) . (As before, activin treatment of animal caps was con®rmed by RNase protection analysis for endogenous gene transcripts; data not shown.) We conclude that each FAST2 site at 25.1 or at 25.2 kb can at least partially compensate for the loss of the other site, in conferring activin responsiveness to the Eomes promoter, and that at least one FAST2 site in this position is absolutely required for Eomes activation in response to activin.
We noticed that each activin responsive FAST2 site (Fig. 5A, F1 and F2; Fig . 5B, thick underlines) is embedded within a 43 bp imperfect direct repeat (Fig. 5B, arrows) . These repeated sequences are separated by unrelated sequence in three blocks of 43 bp each. In an attempt to more sharply de®ne the minimal Eomes activin response element (ARE), we truncated the Eomes promoter at 25.3 kb, at the beginning of the ®rst 43 bp repeat (Fig. 5A , construct 5.3, truncated at nucleotide 25289 (Fig. 5B) ). This retains both 43 bp repeats. We ®nd that the 5.3 kb Eomes-globin construct yields a low absolute level of activin stimulated response in animal caps compared to the 5.6 kb promoter (Fig. 5C , lanes 5.3 versus 5.6, 1activin; longer exposure shown to verify 5.3 response). Despite this, the 5.3 kb promoter (containing both FAST2 sites and direct repeats) is still about half as activin-responsive as the parental 5.6 kb one (Fig. 5D, 5 .3 versus 5.6, compare plus/minus activin ratio). Quantitation further indicates a two-fold reduced baseline activity of the 5.3 kb promoter (Fig. 5D,  5 .3 versus 5.6, both minus activin). These results suggest that the missing sequences between 25.6 and 25.3 kb are more important for increasing the pol II initiation rate than for activin response per se. A more precise de®nition of the minimal Eomes ARE is currently underway.
A visual inspection of the Eomes promoter sequencē anking the ARE reveals two potential Smad binding elements (SBEs) as identi®ed by Zawel et al. (1998) . The ®rst SBE is located 24 bp 3 H of the F1 FAST2 site, while the second is 33 bp downstream of F2 (Fig. 5B, underlined) . These sites consist of a Smad box (GTCT; Shi et al., 1998) followed by GAAC (F1) or GAAT (F2), respectively (see Stroschein et al., 1999) . This is consistent with a requirement for FAST and supports the view that Eomes is activated via the Smad/FAST pathway (see Section 3).
In sum, at least one FAST2 site is required for Eomes responsiveness to activin, and an important stimulatory element is located upstream of the FAST2 sites between 25.6 and 25.3 kb. We now test whether the intervening sequences between the FAST2 sites and the proximal promoter region at 20.25 kb (which represents a minimal, activin non-responsive promoter) affect activin responsiveness. Speci®cally, we wished to know if the Eomes ARE could confer activin responsiveness to a minimal Eomes promoter.
The Eomes ARE confers activin responsiveness to a minimal promoter
In order to test whether the Eomes ARE itself is suf®cient for activin responsiveness, we placed the ARE XbaI-NcoI fragment (25.0 to 25.6 kb) immediately upstream of 20.25 kb and tested this construct (called XN/0.25; Fig.  5A ) in our assay. As shown in Fig. 5C , the Eomes ARE when used to drive a minimal promoter is activin hyperresponsive (XN/0.25 versus 5.6, lane 1A), while the control construct with only 0.25 kb of promoter is unresponsive to activin (lane 0.25^A). However, the baseline level of transcription occurring on XN/0.25 is elevated signi®cantly (lane 2A). This result is consistent with the loss of a repressor element, and was con®rmed by quantitation (Fig. 5D) . Interestingly, the level of baseline transcription driven by the internally deleted XN/0.25 construct (Fig. 5C, lane 2A) is nearly as high as the activated level seen for the intact 5.6 kb Eomes promoter plus activin (lane 1A). However, the activin responsiveness of XN/0.25 is left unchanged relative to 5.6 kb at about ten-fold (Fig. 5D , compare plus/minus activin ratio). We conclude that our data are consistent with the idea of a repressor element or elements located between 25.0 and 20.25 kb within the Eomes promoter.
However, the elevated baseline transcription seen in untreated caps for the XN/0.25 construct raises the possibility that we have simply created an artifactually`leaky' promoter instead of a bona-®de de-repressed one. To distinguish between these two possibilities, we turned to a different kind of assay which would allow us to assess the XN/ 0.25 construct independently of the animal cap assay, in a more physiologically relevant context. Such an assay would be provided in normal, untreated embryonic cells, left to develop undisturbed in situ in their natural context within the embryo. In the case of a generally leaky promoter, we might expect to see a baseline transcriptional level that is similarly elevated to the level seen in untreated caps. This elevated baseline might be expected to occur in (untreated) cells located in different regions within intact embryos irrespective of their location. In contrast, in the case of a missing repressor, one might not expect all cells to be equal in respect of this construct. To determine whether this approach is feasible, we ®rst need to examine whether a fully active Eomes-globin construct is active in embryonic cells when they are left undisturbed and allowed to develop normally.
5.6 kb of the Eomes promoter confers regionally restricted Eomes-globin expression
Having determined that 5.6 kb of upstream Eomes promoter sequence is suf®cient for full activin responsiveness, we wished to know whether this promoter segment was also suf®cient in mimicking the normal expression pattern seen for Eomes. To do this, we injected 5.6 kb Eomes-globin mixed with Ref-globin into cells located in different tiers along the animal vegetal axis of 32-cell embryos (tiers A through D, Fig. 6A ) (Watabe et al., 1995) . Tier A cells are mostly fated to become neuroectoderm and epidermis which do not express Eomes during gastrulation (in the absence of added activin), and therefore should not express injected Eomes-globin. Likewise, tier D cells predominantly represent presumptive endoderm, and left undisturbed in situ in injected embryos also should not activate Eomes-globin expression. In contrast, the equatorial tier C cells are mostly fated to become mesoderm, with the exception of the dorsal most blastomere, which is fated to form dorsal endoderm (Slack, 1991) . Both mesodermal and some dorsal endodermal cells express Eomes at gastrulation (Ryan et al., 1996;  Ryan and Gurdon, in preparation); hence, tier C cells would be expected to strongly activate Eomes-globin constructs should these contain all the necessary information for mesoderm-speci®c expression.
On injection of the 5.6 kb Eomes-globin construct into four representative blastomeres of tiers A, C and D, and allowing the injected embryos to develop until a midgastrula stage (11), we ®nd that Eomes-globin is strongly expressed in the tier C-injected embryos, but not in tiers A and D (Fig. 6B) , approximating the normal mesodermal expression of the endogenous Eomes gene (Ryan et al., 1996) . We conclude that the 5.6 kb Eomes promoter contains all the necessary information for mesodermal expression in this assay. To assess the signi®cance of the elevated baseline transcriptional levels seen for XN/0.25 in caps, we now ask whether this construct yields globally high baseline levels in whole embryos, or if its expression is instead regulated.
A repressor element extinguishes Eomes expression in endoderm
On injection of a mixture of XN/0.25 plus Ref-globin into different tiers of 32-cell embryos (as described above), we obtain the result that this construct is not expressed at equal levels in all cells. Instead, it is expressed at high levels after injection into the C and D tiers, relative to A and B tierinjected cells (Fig. 6C) . In addition, the elevated levels seen for XN/0.25 in the C and D tier-injected whole embryos do not represent a hyper-activation, unlike the levels seen in injected, activin-treated caps (Fig. 5C,D) . This result indicates that the high baseline level of XN/0.25 in untreated caps is unlikely to be attributable to an artifactually leaky promoter. It is much more likely that the high baseline in caps re¯ects the loss of a repressor element that would normally be required to block inappropriate Eomes expression in endoderm. This interpretation gains further weight given a wealth of evidence to show that TGF-b signalling is highly active throughout the vegetal hemisphere in early Xenopus embryos (for a particularly relevant example see Watabe et al., 1995) . We conclude that we have identi®ed a region within the Eomes promoter that behaves as an endoderm-speci®c element, and suggest that it normally works to block inappropriate Eomes transcription in these cells. Determination of the minimal repressor DNA element and its cognate target protein(s) is currently in progress. More importantly for the main thrust of this study, we further conclude that the Eomes ARE is necessary and suf®cient for a high-dose responsiveness of the Eomes promoter to activin.
The Eomes promoter responds directly to activin signalling
One essential feature expected of a gene that directly transduces morphogen gradient signals is that it takes place directly, i.e. without intermediary gene activations. Eomes falls into this class of genes, as it is an immediateearly response to activin mesoderm induction, occurring in the absence of protein synthesis (Ryan et al., 1996) . Hence, it is essential that the Eomes promoter under study should re¯ect this behaviour. To examine this, we tested whether Eomes-globin transcription can occur in response to activin in the presence of cycloheximide (Cascio and Gurdon, 1987) . Fig. 7A shows that Eomes-globin makes an immediate-early response to a mesoderm inducing treatment with activin, even in the presence of cycloheximide (lane CA, compare Eomes-globin to Eomes). Chordin (chd) transcription is dependent on protein synthesis (Sasai et al., 1994) and is shown as a control for cycloheximide effectiveness. Early Xbra transcription is known to occur in the absence of protein synthesis (Smith et al., 1991) and is shown as a positive control, while Ref-globin and the maternal level of FGF-R are unaffected by these treatments and are shown as loading controls. We conclude that Eomes-globin faithfully reproduces the direct response of Eomes to activin treatment.
The Eomes ARE is suf®cient to confer activin concentration responsiveness
A mixture of the 8.5 kb Eomes-globin construct plus Refglobin injected and analyzed as above shows that Eomesglobin responds to mesoderm induction in a dose-dependent way, and that the level of Eomes-globin correlates well with the dose of activin used (Fig. 7B,C , compare boxes and circles). Furthermore, Eomes-globin normalized to Refglobin (Fig. 7C, boxes) very closely approximates Eomes normalized to FGF-R (Fig. 7C, crosses) for each dose of activin used. We conclude that 8.5 kb Eomes-globin contains all of the cis-acting elements required to faithfully reproduce the same activin-response kinetics seen for the endogenous Eomes gene.
To determine whether the Eomes ARE alone is suf®cient to confer activin responsiveness over a wide range of activin doses, we repeated the cap assay using the XN/0.25 construct, and compared the results with those using the complete 8.5 kb promoter. To further assess reproducibility, we also used a different batch of activin protein (see Section 4) for each test. This entailed measuring the actual dose, in each case, of activin received by treated caps, by both morphological (Green et al., 1992 ) and molecular (as described above) criteria. The results indicate that the Eomes ARE can confer activin dose responsiveness over the full range of doses tried (Fig. 8A) , with the exception of the highest dose (see below). The 8.5 kb Eomes-globin control indicates that although there are quantitative differences among different batches of injected eggs in the relative levels of Eomes and Eomes-globin seen in response to activin treatment (compare Figs. 8B and 7C ), Eomes-globin dose responsiveness still very closely parallels that of Eomes. We note that at the highest dose of activin treatment (200 U/ml) using XN/0.25-injected cells, Eomes-globin responds at a signi®cantly higher level than might be expected for Eomes. This is likely to be due to the induction of endoderm at the expense of mesoderm in these caps, because of the very high dose of activin used in this instance. In this case Eomes-globin is free to respond fully to activin since it lacks the endodermal repressor element, while Eomes, with its intact promoter, responds at a lower level due to repression in the induced endodermal cell environment. We conclude that the Eomes ARE is suf®cient to provide the full range of activin concentration responsiveness to activin shown by this gene.
Discussion
We have isolated an Eomes genomic clone with overall 99% identity within the coding region to the original Eomes cDNA and mapped the 5 H end of the Eomes mRNA to a position 34 bp downstream of the TATA box. Fusion of the Eomes promoter to the human b -globin reporter gene provides an in vivo assay for Eomes promoter function (Mohun et al., 1989; Howell and Hill, 1997) . Deletion of upstream promoter sequences reveals an activin response element (ARE) within the Eomes promoter, located between 25.6 and 25.0 kb. This 571 bp DNA fragment contains two binding sites for mouse FAST2, and PCR site-directed mutagenesis reveals that at least one of either of these sites is required for response to activin. Internal deletion of sequences between 25.0 and 20.25 kb within the Eomes promoter reveals (1) that an endodermal repressor element, which resides in the promoter region between 20.25 and 25.0 kb, con®nes Eomes expression to the mesoderm and (2) that the Eomes ARE is necessary and suf®cient for the activin concentration responsiveness of this gene.
Eomes is unique among Xenopus gene promoters analyzed to date in its having a strong activator (the ARE) separated from a strong repressor, where the function is to control germ layer-speci®c gene expression. Other repressors that have been identi®ed in Xenopus promoters are found in genes that are restricted to the dorsal mesoderm (organizer) such as Xlim-1 (Rebbert and Dawid, 1997) and XFD-1 H (Friedle et al., 1998) . These genes differ from Eomes in that they repress expression in ventral mesoderm. In Xlim-1 an intronic repressor is thought to restrict the otherwise constitutive and activin non-responsive activity of Xlim-1 to the organizer, while for XFD-1 H a BMP inhibitory element performs this same function through Xvent-1 binding.
The concentration dependence of Eomes expression is closely paralleled by Eomes-globin, and requires only the Eomes ARE as a mediator of activin signalling, a ®nding which has yet to be reported for other genes. The Eomes ARE has a close juxtapositioning of two FAST protein binding sites, and is the ®rst such ARE in which two closely spaced FAST sites are of demonstrable importance in activin signalling. This close spacing of FAST sites may be a critical determinant in encoding a graded gene response at the promoter level to TGF-b like signalling, and hence would have important implications in explaining how morphogen gradients work at the molecular level. We are thus in a strong position to pursue a molecular analysis of the factors that mediate this tight regulation in response to an experimental morphogen gradient such as can be achieved using activin protein.
Based on our ®ndings reported here, we propose a model for Eomes transcriptional regulation in early Xenopus embryos (Fig. 9) . Activin (or activin-like) signalling via the Smad/FAST pathway ( Fig. 9A) (Chen et al., 1996 (Chen et al., , 1997 Graff et al., 1996; Labbe Â et al., 1998) would be required to activate Eomes in the early embryonic mesoderm, and this signal would lead to the formation of a multi-protein complex at the FAST2 sites within the Eomes ARE. This complex would include Smads 2 and 4, FAST2, p300, and other as yet unidenti®ed proteins (represented as X in Fig. 9 ) that function through interaction with the 5 H half of the Eomes ARE (Fig. 5C,D , 5.3 construct) . This enhancer complex is both necessary and suf®cient for graded responsiveness to activin (Figs. 3B and 5C ), and we propose that it is also important in mesoderm-speci®c Eomes activation in embryos (Fig. 9B) , since Eomes is expressed in an equatorial dorsoventral gradient in normal embryos. In the endoderm, we propose that Eomes transcription is suppressed by an endoderm-speci®c repressor. This repressor might work as a decoy for binding to either the basal transcription machinery or to the Eomes ARE complex, as it interacts with a DNA element that does not physically overlap with the ARE (Fig. 9C) . Thus, activin/ TGF-b signalling that would otherwise inappropriately activate Eomes in the endoderm is blocked.
Materials and methods
Isolation of an Eomes genomic clone
Approximately 2 £ 10 6 plaques of a Xenopus genomic library in Lambda FIX w II (Stratagene) were screened with a random primed cDNA probe corresponding to nucleotides 1±200 of the Eomes mRNA (Ryan et al., 1996) , as described previously (Feinberg and Vogelstein, 1983) . Four positive clones were identi®ed and plaque-puri®ed. Limited sequencing was initially performed for clones 3 and 5 within the 5 H UTR and coding region. Further sequencing of clone 3 revealed a 99% identity to Eomes within the coding region. An apparent 7 bp deletion in genomic clone 3 (at a position corresponding to nucleotide 164) relative to the original Eomes cDNA sequence suggests that this clone would encode a message with a different initiator methionine, corresponding to M27 of the original decoded Eomes protein. Clone 3 was further analyzed by restriction mapping (data not shown) to generate the map shown in Fig. 1D . The entire 14 kb clone was sequenced with the exception of about 500 bp at the 3 H end.
Eomes-globin reporter constructs
To place the entire 8.5 kb Eomes promoter upstream of bglobin (creating a plasmid called 5-656), a partially digested restriction fragment was isolated from the 14 kb Eomes genomic clone 3 (in pBluescript (Stratagene) (Howell and Hill, 1997 ) that had been previously digested with SacI and XbaI, and blunted using T4 DNA polymerase. The order of sites in the 4-627 MCS is: NotI, BssHII, N 6 , PmeI, SmaI, AscI/BssHII, N 6 , NheI, NotI, globin; N 6 signi®es a 6 bp spacer. 5 H deletions were made to the Eomes promoter as follows. The 6.5 and 4.0 kb Eomesglobin deletion constructs were truncated at the corresponding EcoRI sites within the Eomes promoter by digesting 5-656 with PmeI, and then partially with EcoRI. Appropriate length partial digestion products were isolated and plasmids were re-closed using a PmeI-NotI-EcoRI blunt/sticky double stranded DNA adaptor. The 5.6 and 5.0 kb Eomesglobin constructs were made similarly, digesting with PmeI plus XbaI, or plus NcoI, and using the appropriate adaptor. The 1.8 kb Eomes-globin construct was made by excising the 1.8 kb AspI fragment from a 6.5 kb EcoRI-partialBamHI promoter fragment (called 1-259, cloned in Bluescript), blunting this AspI fragment, and re-cloning it in 2102SN-globin that had been cut with SacI and XbaI, and blunted with T4 polymerase. The 253 bp construct was similarly cloned blunt into this same vector by PCR. For the F1m, F2m, and F1F2m constructs, the XbaI-NcoI fragment containing the two distal FAST2 sites was PCR ampli®ed (Expande High Fidelity PCR System, Boehringer catalogue #1 732 641) using the appropriate mutant oligos, and then cloned into the XbaI-NcoI site of the 5.6 kb construct, replacing the natural Eomes sequence. (In this case a two-step PCR was performed, ®rst generating upstream and downstream segments of the 571 bp XbaINcoI fragment, purifying these, and subsequently`splicing' them together in a second PCR.) The XN/0.25 kb construct was made by placing the natural Eomes XbaI-NcoI fragment blunt into a PCR-engineered PmeI site (upstream of and adjacent to 20.25 kb) in a clone called 1-535, which was further digested using NotI and partially using BamHI, then Klenow-blunted and re-closed. The 0.25 kb Eomes-globin construct was generated from 1-535 by digestion with PmeI, partial digestion with BamHI, Klenow blunting and re-closing, and it contains nucleotides 2253 to 1107 of the Eomes gene promoter. The 5.3 kb construct was generated by PCR in which a 5 H -truncated XbaI-NcoI fragment was used to replace the wild type sequence in the 5.6 kb construct. Mutated constructs were sequenced to verify that the desired mutations had been made. Ends of all other constructs were sequenced, except for the 1.8 kb one, which was restriction mapped, to verify the procedure. For each Eomes-globin construct, 50 pg per embryo of supercoiled plasmid DNA was mixed with 80 pg per embryo of Ref-globin and injected into the animal pole at the one-to two-cell stage. To ensure obtaining supercoiled plasmids, these were prepared by standard alkaline lysis (followed by PEG precipitation; Sambrook et al., 1989) , but mixing very gently during the lysis and neutralization steps. Plasmids were further puri®ed using glass milk (Bio 101, Inc., Geneclean II Kit, catalogue #1001-400) prior to injection into Xenopus eggs.
Culturing embryos and producing activin protein in oocytes
Embryos and animal pole explants (caps) were cultured as described (Ryan et al., 1996) , then transferred to 1£ MBG containing normal (0.4 mM) amounts of these divalent cations. Caps were either treated with 32 U/ml activin (Green et al., 1992) or left untreated, except in the case of Fig. 3C where 13 U/ ml activin protein was used instead, and then cultured until the equivalent of stage 11 before freezing them in 1£ MBG in liquid nitrogen for later assay. Activin protein was produced by micro-injection of manually de-folliculated Xenopus oocytes with 50 ng activin bb (Thomsen et al., 1990 ) synthetic mRNA per oocyte. Injected oocytes were cultured in 1£ MBG, in 1% agarose/1£ MBS-coated 96-well plates (12±14 oocytes in 200 ml 1£ MBG per well), for 3 days (removing dead and dying oocytes daily). Each well also contained 10 ml (4.1 MBq) [ 35 S]methionine (43.5 TBq/mmol) per well. After 3 days of culture, the supernatant containing secreted activin protein was collected and centrifuged for 5 s at 12 000 £ g, yielding 1.4 ml supernatant for seven wells. To increase its stability at 2708C, this radiolabeled activin protein was then partially puri®ed by G50 gel ®ltration chromatography (10 ml column) in 1£ MBG at room temperature (248C; Dyson and Gurdon, 1998) . Column fractions containing most (80% of the ®rst-eluting counts) of the activin protein (the ®rst-eluting radioactive peak, assayed by scintillation counting) were pooled, frozen in 20 ml aliquots on dry ice and stored at 2708C. Four different activin protein preparations were used in the experiments described in Figs. 7 and 8; two were prepared as described above (Figs. 7A,B and 8B ) and two were used as unlabeled oocyte conditioned media (Figs. 7C and 8A ). Cycloheximide treatment of caps was performed as described (Cascio and Gurdon, 1987; Smith et al., 1991; Ryan et al., 1996) .
RNase protection and primer extension analysis
RNase protection was performed as previously described (Ryan et al., 1996) . To reduce variability due to mosaic expression of injected DNA in Xenopus cap assays (Howell and Hill, 1997) , 15 reporter plasmid-injected caps were pooled per plasmid DNA construct and frozen in liquid nitrogen. RNA was prepared for each sample as described (Ryan et al., 1996) , and one-tenth (1.5 caps' worth) was removed and assayed separately for endogenous gene transcripts (Eomes, Xbra, and FGF-R), while the remaining nine-tenths was assayed for human b -globin transcripts. To reduce batch variation, injected constructs and controls were assayed in parallel in eggs from the same female. Quantitation was performed for all RNase protection gels using a Fuji®lm BAS-2500 PhosphorImager and MacBAS V2.5 software. Primer extension analysis was performed using standard methodology (Sambrook et al., 1989 ) using 6 mg per primer of poly A1 RNA selected from gastrula stage embryos, except for the following modi®cations. After cDNA synthesis using reverse transcriptase, samples were digested in 100 ml with RNase A (5 mg/ml, 15 min at 378C), and then with Proteinase K (0.5 mg/ml, 0.5% SDS, 15 min at 378C). Digested samples were phenol extracted and ethanol precipitated with 10 mg carrier tRNA before re-suspension in 8 ml formamide dyes (20 mM EDTA, 0.03% xylene cyanol, 0.03% Bromophenol Blue in formamide) and electrophoresis on 6% polyacrylamide/urea gels. The sequence of extension primers used is: EP59, 5
H -TCCTCTGACTGC-GATTCTCTTCTTTTTCTGAAGCAGAACTTG-3 H ; EP60, 5
H -TGCGATTCTCTTCTTTTTCTGAAGCAGAACTTG-TAGTAAATAATAGGG-3 H ; EP61, 5 H -CTTTTTCTGAA-GCAGAACTTGTAGTAAATAATAGGGAGTGCCAGG-CAC-3 H ; 10 pmol of each primer was end-labelled and puri®ed (Sambrook et al., 1989) , and 10 6 cpm (,1 pmol) was used per primer extension reaction.
Electrophoretic mobility shift analysis
FAST proteins were produced in vitro from cDNA plasmids (Bourillot and Gurdon, in preparation) using the TnT system (Promega). DNA probes were generated from F1m, F2m, F1F2m and 5.6 kb (WT) Eomes-globin constructs by excision of a 253 bp PstI-NcoI fragment which constitutes approximately the 3 H half of the Eomes ARE, containing both FAST2 sites, F1 and F2, and both 43 bp repeats (Fig.  5B ). Digests were de-phosphorylated using calf intestinal alkaline phosphatase (Boehringer). These 253 bp Eomes probes were end-labelled with 32 P using standard methodology (Sambrook et al., 1989) , puri®ed on an acrylamide gel and eluted in DNA elution buffer (0.5 M ammonium acetate, 10 mM magnesium acetate, 1 mM EDTA, 0.1% SDS). Probe eluates were ethanol (2.5 vol) precipitated and dissolved in 10±20 ml TE (to ,30 000 cpm/ml). Binding reactions were carried out in 20 ml each in binding buffer (20 mM HEPES (pH 7.9), 8% glycerol, 2 mM EDTA, 2 mM DTT, 7.2 mM MgCl 2 ), to which was added (in order) 2 ml [ 35 S]FAST2 protein, 0.1 mg/ml ®nal concentration (Fc) poly-[dIdC-dIdC] (Pharmacia; average size 500 bp), 0.5 mg/ml Fc BSA, and DNA probe (30 000 cpm per reaction). Samples were gently mixed and binding was allowed to occur at room temperature (248C) for 30 min. A 4.5% non-denaturing polyacrylamide gel (14 cm £ 18 cm £ 1 mm) was made in and pre-run in 0.2£ TBE for 30 min at 150 V. After pre-running, reactions were electrophoresed at 150 V with blue dyes (0.1% xylene cyanol, 0.1% Bromophenol Blue, 5% glycerol) run in a side lane, until the xylene cyanol had moved 3/4 gel length (,3.5 h). The gel was dried and exposed to X-ray ®lm overnight.
